HeiQ's Transition to Private Trading: A Strategic Shift for Growth

HeiQ Plc delisted from the London Stock Exchange in 2024 to reduce costs and focus capital on scaling key ventures like AeoniQ™ and GrapheneX, now trading via private auctions.

In a strategic move to reshape its operations, HeiQ Plc delisted from the London Stock Exchange in late 2024. The company's leadership determined that the regulatory demands and administrative costs associated with maintaining a public listing were impeding progress. Consequently, trading in HeiQ shares now occurs within a private marketplace, a setting that demands patience and a revised strategy from investors. Price discovery is no longer continuous but is instead established periodically through a specialized auction process.

A New Framework for Investment and Valuation

The departure from the public exchange in November 2024 was calculated to free up resources. Management identified the listing's overhead as a barrier to advancing its innovation divisions. The core objective is to deploy capital more efficiently into the scaling phases of key projects, notably HeiQ AeoniQ™ and HeiQ GrapheneX. These venture units are central to the firm's long-term plan for growth in sustainable textile alternatives and advanced material technologies.

This new private structure, however, comes with a trade-off: shares are no longer liquid assets that can be bought or sold at any moment. The focus has shifted toward targeted private funding rounds. This approach is designed to allow for more directed investment into high-growth areas while simultaneously streamlining the core business for cost efficiency.

Understanding the Private Auction Process

Transactions are currently facilitated through the Asset Match platform. Here, investors can review bids and offers, but trading is confined to specific windows rather than occurring in real-time. The current auction cycle is drawing to a close, with the next result anticipated between February 26 and March 25, 2026. Any trading activity must be initiated through an investor's broker.

Beyond its materials technology ventures, HeiQ is also channeling increased investment into its Life Sciences division, which specializes in probiotic industrial biotechnology. The conclusion of the present auction phase on March 25, 2026, will provide the next concrete data point for assessing the share's valuation in this private market environment.